Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

749.92 -3.49 (-0.46%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
$1000 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
Via Benzinga
2 High-Flying Growth Stocks With Massive Upside Potential
These innovative drugmakers have potential catalysts ahead. 
Via The Motley Fool
This is Huge News For Eli Lilly Investors
Eli Lilly is investing billions into new research and manufacturing capabilities. 
Via The Motley Fool
Exploring NYSE:LLY's high growth characteristics.
Delving into ELI LILLY & CO (NYSE:LLY)'s high Growth Prospects. 
Via Chartmill
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate. 
Via The Motley Fool
Eli Lilly Unusual Options Activity
Via Benzinga
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide. 
Via Investor's Business Daily
Exposures Product Safety
This Artificial Intelligence Move Is One New Reason to Buy Eli Lilly Stock in 2024
Lilly is staying ahead of the technology curve instead of falling behind. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run. 
Via The Motley Fool
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Lilly has invested billions of dollars to ramp up production capacity. 
Via The Motley Fool
Exposures Product Safety
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Jim Cramer believes Uranium Energy Corp. is going higher, thanks to a recent acquisition deal. Novo Nordisk faces antitrust concerns while Halliburton gets a Buy rating from BofA Securities. 
Via Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory hurdles amid ongoing trials and safety concerns. 
Via Benzinga
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own... 
Via Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
An industry group sued the FDA, claiming tirzepatide remains in shortage. 
Via Investor's Business Daily
Topics Lawsuit
Exposures Financial Legal Product Safety
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s... 
Via Benzinga
'Most Widely Hated' Bull Market Reaches 2-Year Milestone: Top 20 S&P 500 Stocks Driving The Rally
S&P 500 bull market defies expectations with 63% gains in 2 years, led by technology sector. Top performers include Nvidia, Super Micro Computer, and Vistra Corp. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
These two stocks will appeal to very different types of investors at the moment. 
Via The Motley Fool
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, sparking legal and industry pushback. 
Via Benzinga
Exposures Product Safety
3 No-Brainer Growth Stocks to Buy in October
These stocks look like slam-dunk picks for growth investors. 
Via The Motley Fool
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there. 
Via MarketBeat
Got $500? 2 Magnificent Growth Stocks to Buy and Hold Forever
These industry leaders still look like top-notch buys. 
Via The Motley Fool
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock. 
Via Talk Markets
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say
Counterfeit and diverted weight loss drugs like Ozempic and Mounjaro are flooding international markets, posing serious health risks. Authorities are cracking down on illegal shipments as... 
Via Benzinga
Topics Law Enforcement
Exposures Legal
Sustainability Of Energy Stocks Is Clouded By 2024 Election Uncertainty
Here's what investors should know about what's at stake for sustainable companies. 
Via Investor's Business Daily
Warning: This Skyrocketing Stock Has a Hidden Risk
Eli Lilly stock has jumped 200% over the past two years. 
Via The Motley Fool
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the merger could harm competition in the GLP-1 market, potentially driving up... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.